Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2013

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C

Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.

RADIATION

Radiation Therapy

Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks

Trial Locations (15)

1001

Auckland Hospital, Auckland

2031

Prince of Wales Hospital, Randwick

2145

Westmead Hospital, Wentworthville

2298

Calvary Mater Newcastle, Newcastle

2605

The Canberra Hospital, Garran

3220

Andrew Love Cancer Centre, Geelong Hospital, Geelong

4029

Royal Brisbane Hospital, Herston

4101

Mater QRI, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4224

Premion - Tugun, Tugun

4710

Christchurch Hospital, Christchurch

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

8006

Peter MacCallum Cancer Centre, Melbourne

Unknown

Illawarra Cancer Care Centre, Wollongong

All Listed Sponsors
collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00193973 - Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter